Would you give dasatinib to a standard risk pre-B ALL patient with an ABL1 mutation?

I would like to revise my previous answer to this excellent question slightly. While we still do not have solid data to know how to manage such patients, the COG Ph+ B-ALL study (AALL1631) is now open to enrolling Ph-like B-ALL patients with ABL-class fusions regardless of NCI status. Thus, I would ...